中国临床药理学杂志Issue(9)：725-727,3.DOI:10.13699/j.cnki.1001-6821.2015.09.014
曲妥珠单抗新辅助化疗表皮生长因子受体2阳性乳腺癌的临床疗效及安全性评价
Study on efficacy and safety of trastuzumab chemotherapy for the treatment of human epidermal growth factor receptor-2 positive breast cancer
摘要
Abstract
Objective To evaluate the efficacy and safety of neoadjuvantchemotherapy of trastuzumab combined with paclitaxel on human epidermalgrowth factor receptor -2 (HER2) positive breast cancer.Methods A total of 36 patients with breast cancer were included in this study.Patients in this study were given trastuzumab combined with paclitaxelneoadjuvant chemotherapy.Paclitaxel 175 mg· m-2 through intravenousinjection in 3 h on day 1 followed by trastuzumab 8 mg· kg-1 (burdendosage) on day 2 for cycle 1.And for cycle 2 to 4, paclitaxel remainedthe same, followed by trastuzumab 6 mg· kg-1 .Each chemotherapycycle was 21 days.After 4 cycles of chemotherapy treatment, the data ofclinical efficacy and toxicity were evaluated.Results All of the 36 casesfinished the neoadjuvant chemotherapy.The case of completeresponse, partial response were 18 and 13 and and objective responserate (ORR) was 86.11%.There was no statistical difference in ORRamong the subgroup analysis (P >0.05).The main adverse reactionswere granulocytopenia (13.88%) and fatigue (61.11%) during thechemotherapy.Conclusion High clinical efficacy and less adversereactions are found in the treatment of trastuzumab combined withpaclitaxel for HER2 -positive breast cancer.关键词
乳腺癌/曲妥珠单抗/新辅助化疗/表皮生长因子受体2/临床疗效Key words
breast cancer/trastuzumab/neoadjuvant chemotherapy/human epidermal growth factor receptor 2/clinical efficacy分类
医药卫生引用本文复制引用
殷科,曹永晋..曲妥珠单抗新辅助化疗表皮生长因子受体2阳性乳腺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,(9):725-727,3.基金项目
浙江省卫生厅青年科研基金资助项目 （）
